Ohtuvayre (Ensifentrine) - Is Ensifentrine covered by Medicare?

Ohtuvayre (Ensifentrine) - Ensifentrine is a new drug indicated for the treatment of chronic obstructive pulmonary disease (COPD) in adults, specifically for the maintenance treatment of COPD. The drug is administered primarily by inhalation, and its mechanism of action involves the inhibition of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4). Exefantine is more than 3,000 times more potent on PDE3 than PDE4, so it has significant bronchodilator and anti-inflammatory effects.

Currently,The original version of Ohtuvayre has not yet been launched in the Chinese market, resulting in its specific price and medical insurance policy still unknown. Therefore, patients need to pay attention to relevant regulatory developments and whether it is included in medical insurance before using this drug. Ohtuvayre is a new type of drug that enters the body through aerosol inhalation and helps relieve breathing difficulties caused by chronic obstructive pulmonary disease and asthma.

Clinical studies have shown that exefantine can effectively reduce the levels of pro-inflammatory cytokines (such as granulocytes-macrophage colonial factor GM-CSF), thereby exerting anti-inflammatory effects. In addition, it has been shown in in vitro experiments to activate CFTR (cystic fibrosis transport regulator protein) in bronchial epithelial cells, thereby promoting the secretion of chloride ions, increasing the frequency of ciliary movement, and possibly improving mucus clearance.

In animal models, exefentine has been shown to have a protective effect against spasmodogen- and antigen-induced airway contraction, demonstrating dose-dependent bronchodilatory properties. These preclinical and clinical study results indicate that exefantine has good application prospects as a treatment option for COPD and asthma.

Although exefantine has shown many advantages, since it is not marketed in China, patients still need to be cautious when choosing treatment options and pay close attention to relevant policies and market dynamics. At the same time, doctors recommend that patients should follow professional guidance when using any new drugs to ensure safety and efficacy.

Reference materials:https://en.wikipedia.org/wiki/Ensifentrine